Journal of Diabetes and Its Complications
Volume 19, Issue 1 , Pages 60-64 , January 2005

Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets

  • Silvia Del Guerra

      Affiliations

    • Metabolic Unit, Department of Endocrinology and Metabolism, Cisanello Hospital-Pisa, Pisa 56100, Italy
    • ,
  • Lorella Marselli

      Affiliations

    • Metabolic Unit, Department of Endocrinology and Metabolism, Cisanello Hospital-Pisa, Pisa 56100, Italy
    • ,
  • Roberto Lupi

      Affiliations

    • Metabolic Unit, Department of Endocrinology and Metabolism, Cisanello Hospital-Pisa, Pisa 56100, Italy
    • ,
  • Ugo Boggi

      Affiliations

    • Transplant Unit, Department of Oncology, Ospedale Cisanello, University of Pisa, Italy
    • ,
  • Franco Mosca

      Affiliations

    • Metabolic Unit, Department of Endocrinology and Metabolism, Cisanello Hospital-Pisa, Pisa 56100, Italy
    • ,
  • Luca Benzi

      Affiliations

    • Metabolic Unit, Department of Endocrinology and Metabolism, Cisanello Hospital-Pisa, Pisa 56100, Italy
    • ,
  • Stefano Del Prato

      Affiliations

    • Metabolic Unit, Department of Endocrinology and Metabolism, Cisanello Hospital-Pisa, Pisa 56100, Italy
    • ,
  • Piero Marchetti

      Affiliations

    • Metabolic Unit, Department of Endocrinology and Metabolism, Cisanello Hospital-Pisa, Pisa 56100, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 050 995110; fax: +39 050 541521

Received 30 June 2003 ,Revised 16 April 2004 ,Accepted 12 May 2004.

References 

  1. Anello M, Gilon P, Henquin JC. Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content. British Journal of Pharmacology. 1999;127:1883–1891
  2. Ball AJ, Flatt PR, McClenaghan NH. Desensitizazion of sulphonylurea and nutrient-induced insulin secretion following prolonged treatment with glibenclamide. European Journal of Pharmacology. 2000;408:327–333
  3. Davies MJ. Insulin secretagogues. Current Medical Research and Opinion. 2002;18(Suppl 1):s22–s30
  4. De Vos A, Heimberg H, Quartier E, Huypens P, Bouwens L, Pipeleers D, et al. Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. Journal of Clinical Investigation. 1995;96:2489–2495
  5. Giannaccini G, Lupi R, Trincavelli ML, Navalesi R, Betti L, Marchetti P, et al. Characterization of sulfonylurea receptors in isolated human pancreatic islets. Journal of Cellular Biochemistry. 1998;71:182–188
  6. Gribble F, Reimann F. Differential selectivity of insulin secretagogues. Mechanisms, clinical implications and drug interactions. Journal of Diabetes and its Complications. 2003;17:11–15
  7. Hakan P, Borg LA, Andersson A. Long-term effects of glibenclamide on the insulin production, oxidative metabolism and quantitative ultrastructure of mouse pancreatic islets maintained in tissue culture at different glucose concentrations. Acta Diabetologica Latina. 1981;18:65–83
  8. Henquin JC. Tolbutamide stimulation and inhibition of insulin release: studies of underlying ionic mechanisms in isolated rat islets. Diabetologia. 1980;18:151–160
  9. Hoechst AG, Muller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Hormone and Metabolic Research. 1996;28:464–468
  10. Iwakura T, Fujimoto S, Inada A, Kubota A, Someya Y, Ihara Y, et al. Sustained enhancement of Ca(2+) influx by glibenclamide induces apoptosis in RINm5F cells. Biochemical and Biophysical Research Communications. 2000;271:422–428
  11. Karam JH, Sanz N, Salamon E, Nolte MS. Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. Diabetes. 1986;35:1314–1320
  12. Langtry HD, Balfour JA. Glimepiride: a review of its use in the management of type 2 diabetes mellitus. Drugs. 1998;55:563–584
  13. Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. American Journal of Physiology, Endocrinology and Metabolism. 2004;286:E560–E567
  14. Lupi R, Dotta F, Marselli L, Del Guerra S, Masini M, Santangelo C, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bel-2 regulated. Diabetes. 2002;51:1437–1442
  15. Lupi R, Marchetti P, Giannarelli R, Coppelli A, Tellini C, Del Guerra S, et al. Effects of glibenclamide and metformin (alone or in combination) on insulin release from isolated human pancreatic islets. Acta Diabetologica. 1997;34:46–48
  16. Marchetti P, Lupi R, Federici M, Marselli L, Masini M, Boggi U, et al. Insulin secretory function is impaired in isolated human islets carrying the Gly(972)–>Arg IRS-1 polymorphism. Diabetes. 2002;51:1419–1424
  17. Marchetti P, Navalesi R. Pharmacokinetic–pharmacodinamic relationships of oral hypoglycemic agents. An update. Clinical Pharmacokinetics. 1989;16:100–128
  18. Marselli L, Dotta F, Piro S, Santangelo C, Masini M, Lupi R, et al. Th2 cytokines have a partial, direct protective effect on the function and survival of isolated human islets exposed to combined proinflammatory and Th1 cytokines. Journal of Clinical Endocrinology and Metabolism. 2001;86:4974–4978
  19. Muller G, Hartz D, Punter J, Okonomopulos R, Kramer W. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor: I. Binding characteristics. Biochimica et Biophysica Acta. 1994;1191:267–277
  20. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51(Suppl 3):s368–s376
  21. Rabuazzo MA, Buscema M, Vinci C, Caltabiano V, Vetri M, Forte F, et al. Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms. Endocrinology. 1992;131:1815–1820
  22. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005–2012Jun 2
  23. Yamato E, Ikegami H, Tahara Y, Fukuda M, Cha T, Kawaguchi Y, et al. Glyburide enhances insulin gene expression and glucose induced insulin release in isolated rat islets. Biochemical and Biophysical Research Communications. 1994;199:327–333

PII: S1056-8727(04)00054-6

doi: 10.1016/j.jdiacomp.2004.05.001

Journal of Diabetes and Its Complications
Volume 19, Issue 1 , Pages 60-64 , January 2005

Article Tools

* Image Usage & Resolution